Novo Nordisk and CAS establish research foundation in China  

2007.03.13
Novo Nordisk establishes a joint research foundation in China, with the aim of funding activities of common interest in the fields of diabetes and biopharmaceuticals
Novo Nordisk and the Chinese Academy of Science (CAS) have signed an agreement that establishes a joint research foundation in China, with the aim of funding activities of common interest in the fields of diabetes and biopharmaceuticals. Novo Nordisk has initially donated DKK 12 m (USD 2 m) to the foundation.
 
Professor Chen Zhu, CAS vice president comments “We look forward to a fruitful cooperation with Novo Nordisk. Chinese and Danish scientists share a history of excellent collaborations which the new foundation will further strengthen. Novo Nordisk is well recognised in China for its major role in preventing and treating diabetes.”
 
Dr Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk says: "This cooperation illustrates the great attention Novo Nordisk pays to China as well as our long-term commitment to help in further developing the Chinese healthcare system.”
 
He also emphasises that Novo Nordisk will continue to launch new products in China and increase the company’s R&D presence in the country. 
 
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company also has a leading position in haemostasis management, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London.
 
Link > Novo Nordisk  

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×